{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:11:22Z","timestamp":1767165082318,"version":"build-2238731810"},"reference-count":16,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Spanish specialist outpatient clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>403 adults with DM2 initiating GLP-1Ra treatment were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Sociodemographic and DM2-related clinical data, including treatment at and after GLP-1Ra initiation and comorbidities, were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evaluable patients (n=403; 50.9% female) were included (July 2013 to March 2014) at 24 centres by 53 specialists (47 endocrinology, 6 internal medicine), with the following profile (value\u00b1SD): age (58.3\u00b110.4\u2005years), diabetes duration (9.9\u00b17\u2005years), body mass index (BMI; 36.2\u00b15.5) and glycated haemoglobin (HbA1c; 8.4\u00b11.4%); 14% had HbA1c\u22647%. Previous antidiabetic treatment: 53.8% only oral antidiabetic drugs (OADs), 5.2% insulin and 40% insulin and OAD; of those receiving OAD, 35% single drug, 38.2% 2 drugs and 24% 3 drugs. Concomitant to GLP-1Ra, 55.3% were only on OAD, 36.2% on insulin and OAD, and 7.2% only on insulin. Of those receiving OAD, the GLP-1Ra was mainly associated with 1 drug (65%) or 2 drugs (31.8%). GLP-1Ra are frequently added to existing antidiabetic drugs, with dipeptidyl peptidase-4 inhibitors being the OAD most frequently switched (45% receiving 1 before starting GLP-1Ra, only 2.7% receiving it concomitantly).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Spain, GLP-1Ra therapy is usually started in combination with OADs or OADs and insulin. These drugs are used in relatively young patients often not reaching therapeutic goals with other treatment combinations, roughly a decade after diagnosis and with a relatively high BMI. The latter could be explained by Spanish regional payers limiting reimbursed prescription to patients with a minimum BMI threshold (&gt;30 in most regions, &gt;35 in some).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010197","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T20:07:56Z","timestamp":1469650076000},"page":"e010197","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain"],"prefix":"10.1136","volume":"6","author":[{"given":"Ignacio","family":"Conget","sequence":"first","affiliation":[{"name":"Diabetes Unit, ICMDM Hospital Cl\u00ednic i Universitari, Barcelona, Spain"},{"name":"CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00eddac","family":"Mauricio","sequence":"additional","affiliation":[{"name":"CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM)"},{"name":"Department of Endocrinology & Nutrition, Health Sciences Research Institute and Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Ortega","sequence":"additional","affiliation":[{"name":"Medical Department, GlaxoSmithKline, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Detournay","sequence":"additional","affiliation":[{"name":"CEMKA-EVAL, Bourg-la-Reine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,7,26]]},"reference":[{"key":"2025121508573565000_6.7.e010197.1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1047"},{"key":"2025121508573565000_6.7.e010197.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2336-9"},{"key":"2025121508573565000_6.7.e010197.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2013.03.002"},{"key":"2025121508573565000_6.7.e010197.4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/dme.12137","article-title":"Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK","volume":"30","author":"Hall","year":"2013","journal-title":"Diabet Med"},{"key":"2025121508573565000_6.7.e010197.5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1472-6823-13-20","article-title":"Medication utilization patterns among type 2 diabetes patients initiating exenatide BID or insulin glargine: a retrospective database study","volume":"13","author":"Pawaskar","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"2025121508573565000_6.7.e010197.6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-012-0015-6","article-title":"A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice","volume":"4","author":"Evans","year":"2013","journal-title":"Diabetes Ther"},{"key":"2025121508573565000_6.7.e010197.7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ijcp.12575","article-title":"Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care","volume":"69","author":"Nyeland","year":"2015","journal-title":"Int J Clin Pract"},{"key":"2025121508573565000_6.7.e010197.8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1185\/03007995.2016.1147025","article-title":"Physician perceptions of GLP-1 receptor agonists in the UK","volume":"32","author":"Matza","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2025121508573565000_6.7.e010197.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"2025121508573565000_6.7.e010197.10","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1679"},{"key":"2025121508573565000_6.7.e010197.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02872.x"},{"key":"2025121508573565000_6.7.e010197.12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2369-14-46","article-title":"Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study","volume":"14","author":"Rodriguez-Poncelas","year":"2013","journal-title":"BMC Nephrol"},{"key":"2025121508573565000_6.7.e010197.13","unstructured":"Victoza European Prescribing Information. http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/001026\/WC500050017.pdf (accessed 29 Sep 2014)."},{"key":"2025121508573565000_6.7.e010197.14","unstructured":"Lyxumia European Prescribing Information. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2013\/20130201125120\/anx_125120_es.pdf (accessed 29 Sep 2014)."},{"key":"2025121508573565000_6.7.e010197.15","unstructured":"Byetta European Prescribing Information. http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000698\/WC500051845.pdf (accessed 29 Sep 2014)."},{"key":"2025121508573565000_6.7.e010197.16","unstructured":"Bydureon European Prescribing Information. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2011\/20110617103730\/anx_103730_es.pdf (accessed 29 Sep 2014)."}],"updated-by":[{"DOI":"10.1136\/bmjopen-2015-010197corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:57:44Z","timestamp":1765817864000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,26]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1136\/bmjopen-2015-010197"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010197","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}